Our resultshelp explain why pathological mutations in CB1 (e.g., chronicpain) do not always provide insight into the side effects of CB1 suppression (e.g., clinical depression), and thus urge morepreclinical studies for any drugs that suppress CB1. This evidence concerns the gene CNR1 and depressive symptom measurement.